Search Results

Agilent Technologies, Inc. announced Simon May has been named president of the company’s Diagnostics and Genomics Group.

BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies.

Aranscia, a leading provider of personalized diagnostic solutions, and Signature RX, a leading pharmacy supplier and 503B manufacturer, announced a partnership to develop novel biomarkers and a personalized medication management solution for the effective use of GLP-1 medications.

FDNA Inc, the leader in the early detection of rare genetic diseases, and Genome Medical, the nation’s leading telehealth provider of genetic services, have partnered to empower parents to detect potential developmental, neurological and genetic conditions in their children and connect with specialists quickly – a move that may shorten the diagnostic odyssey for children from an average of five years to a few months.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

Nucleus Genomics announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Epigenica today unveiled its EpiFinder™ Platform with a patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology and launched EpiFinder Genome for comprehensive genome-wide profiling.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech company developing the industry’s leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology